Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-05-15 5:47 pm Sale | 2025-03-31 | 13G | ORIC Pharmaceuticals, Inc. ORIC | Venrock Healthcare Capital Partners III, L.P. | 3,182,527 4.500% | -1,245,858 (-28.13%) | Filing History |
| 2025-05-15 5:46 pm Sale | 2025-03-31 | 13G | Applied Therapeutics, Inc. APLT | Venrock Healthcare Capital Partners III, L.P. | 5,567,709 4.100% | -6,237,592 (-52.84%) | Filing History |
| 2025-05-15 5:45 pm Sale | 2025-03-31 | 13G | Praxis Precision Medicines, Inc. PRAX | Venrock Healthcare Capital Partners III, L.P. | 1,016,497 4.900% | -173,843 (-14.60%) | Filing History |
| 2025-05-15 5:44 pm Purchase | 2025-03-31 | 13G | Cidara Therapeutics, Inc. CDTX | Venrock Healthcare Capital Partners III, L.P. | 417,541 9.900% | 417,541 (New Position) | Filing History |
| 2025-05-15 5:44 pm Sale | 2025-03-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | Venrock Healthcare Capital Partners III, L.P. | 677,600 1.500% | -2,274,771 (-77.05%) | Filing History |
| 2025-05-15 5:43 pm Purchase | 2025-03-31 | 13G | Zura Bio Limited ZURA | Venrock Healthcare Capital Partners III, L.P. | 7,031,271 9.900% | 177,671 (+2.59%) | Filing History |
| 2025-05-05 4:26 pm Purchase | 2025-04-28 | 13G | Jade Biosciences, Inc. JBIO | Venrock Healthcare Capital Partners III, L.P. | 3,220,369 9.900% | 3,220,369 (New Position) | Filing History |
| 2025-04-02 4:49 pm Purchase | 2025-03-26 | 13G | Surrozen, Inc. SRZN | Venrock Healthcare Capital Partners III, L.P. | 872,546 9.900% | 872,546 (New Position) | Filing History |
| 2025-02-27 6:43 pm Purchase | 2025-02-10 | 13G | Oruka Therapeutics, Inc. ORKA | Venrock Healthcare Capital Partners III, L.P. | 4,148,428 11.100% | 606,487 (+17.12%) | Filing History |
| 2025-02-14 6:15 pm Sale | 2024-12-31 | 13G | Mersana Therapeutics, Inc. MRSN | Venrock Healthcare Capital Partners III, L.P. | 410,312 8.300% | -42,808 (-9.45%) | Filing History |
| 2025-02-14 6:15 pm Purchase | 2024-12-31 | 13G | enGene Holdings Inc. ENGN | Venrock Healthcare Capital Partners III, L.P. | 5,046,414 9.900% | 1,480,573 (+41.52%) | Filing History |
| 2025-02-14 6:14 pm Sale | 2024-12-31 | 13G | Century Therapeutics, Inc. IPSC | Venrock Healthcare Capital Partners III, L.P. | 3,957,186 4.700% | -1,432,073 (-26.57%) | Filing History |
| 2025-02-14 6:13 pm Sale | 2024-12-31 | 13G | Astria Therapeutics, Inc. ATXS | Venrock Healthcare Capital Partners III, L.P. | 2,457,348 4.400% | -1,001,297 (-28.95%) | Filing History |
| 2025-02-14 6:12 pm Sale | 2024-12-31 | 13G | Aquestive Therapeutics, Inc. AQST | Venrock Healthcare Capital Partners III, L.P. | 2,629,786 2.900% | -2,925,769 (-52.66%) | Filing History |
| 2025-02-14 6:11 pm Purchase | 2024-12-31 | 13G | Applied Therapeutics, Inc. APLT | Venrock Healthcare Capital Partners III, L.P. | 11,805,301 9.900% | 149,236 (+1.28%) | Filing History |
| 2025-02-14 6:10 pm Unchanged | 2024-12-31 | 13G | Adverum Biotechnologies, Inc. ADVM | Venrock Healthcare Capital Partners III, L.P. | 0 0.000% | 0 (Unchanged) | Filing History |
| 2025-02-14 6:09 pm Sale | 2024-12-31 | 13G | 4D Molecular Therapeutics, Inc. FDMT | Venrock Healthcare Capital Partners III, L.P. | 2,952,371 6.400% | -1,447,629 (-32.90%) | Filing History |
| 2025-02-14 6:08 pm Purchase | 2024-12-31 | 13G | Praxis Precision Medicines, Inc. PRAX | Venrock Healthcare Capital Partners III, L.P. | 1,190,340 6.100% | 283,854 (+31.31%) | Filing History |
| 2025-02-14 6:06 pm Unchanged | 2024-12-31 | 13G | Spyre Therapeutics, Inc. SYRE | Venrock Healthcare Capital Partners III, L.P. | 2,685,448 4.600% | 0 (Unchanged) | Filing History |
| 2025-02-14 6:05 pm Unchanged | 2024-12-31 | 13G | Viridian Therapeutics, Inc. VRDN | Venrock Healthcare Capital Partners III, L.P. | 3,575,309 4.500% | 0 (Unchanged) | Filing History |